Analysis of ongoing SHM of IgVh genes in monoclonal B-cell PTLDs
. | . | Phenotype . | . | . | . | Closest IgVh germ-line gene . | % of mutations . | No. of unconfirmed mutations . | No. of confirmed ongoing mutations . | No. of clones with ongoing mutations . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case . | Histology . | BCL6 . | MUM1 . | CD138 . | EBV . | . | . | . | . | . | ||
| 3515 | P-PTLD | − | − | − | − | 3-15 | 10.3 | 1 | 0 | 0 | ||
| 3519 | P-PTLD | − | + | − | − | 3-30 | 10.3 | 0 | 0 | 0 | ||
| 2898 | DLBCL, centroblastic | + | − | − | − | 4-34 | 11.8 | 0 | 0 | 0 | ||
| 3459 | DLBCL, centroblastic | + | + | − | + | 1-69 | 17.6 | 0 | 4 | 20 | ||
| 3518 | DLBCL, centroblastic | + | − | − | + | 3-33 | 4.41 | 13 | 9 | 20 | ||
| 3522 | DLBCL, centroblastic | + | + | − | − | 4-34 | 6.87 | 6 | 4 | 17 | ||
| 3524 | DLBCL, centroblastic | − | − | − | − | 3-15 | 14.9 | 0 | 0 | 0 | ||
| 3528 | DLBCL, centroblastic | + | − | − | − | 1-18 | 8.11 | 0 | 2 | 3 | ||
| 3530 | DLBCL, centroblastic | − | + | + | − | 3-07 | 24.1 | 0 | 0 | 0 | ||
| 3476 | DLBCL, immunoblastic | − | + | + | + | 4-04 | 8.62 | 0 | 0 | 0 | ||
| 3517 | DLBCL, immunoblastic | ND | ND | ND | − | 3-23 | 7.80 | 0 | 0 | 0 | ||
| 3525 | DLBCL, immunoblastic | − | + | − | − | 4-34 | 2.12 | 0 | 0 | 0 | ||
| 2890 | BL/BLL | ND | ND | ND | − | 4-61 | 12.0 | 12 | 3 | 20 | ||
. | . | Phenotype . | . | . | . | Closest IgVh germ-line gene . | % of mutations . | No. of unconfirmed mutations . | No. of confirmed ongoing mutations . | No. of clones with ongoing mutations . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case . | Histology . | BCL6 . | MUM1 . | CD138 . | EBV . | . | . | . | . | . | ||
| 3515 | P-PTLD | − | − | − | − | 3-15 | 10.3 | 1 | 0 | 0 | ||
| 3519 | P-PTLD | − | + | − | − | 3-30 | 10.3 | 0 | 0 | 0 | ||
| 2898 | DLBCL, centroblastic | + | − | − | − | 4-34 | 11.8 | 0 | 0 | 0 | ||
| 3459 | DLBCL, centroblastic | + | + | − | + | 1-69 | 17.6 | 0 | 4 | 20 | ||
| 3518 | DLBCL, centroblastic | + | − | − | + | 3-33 | 4.41 | 13 | 9 | 20 | ||
| 3522 | DLBCL, centroblastic | + | + | − | − | 4-34 | 6.87 | 6 | 4 | 17 | ||
| 3524 | DLBCL, centroblastic | − | − | − | − | 3-15 | 14.9 | 0 | 0 | 0 | ||
| 3528 | DLBCL, centroblastic | + | − | − | − | 1-18 | 8.11 | 0 | 2 | 3 | ||
| 3530 | DLBCL, centroblastic | − | + | + | − | 3-07 | 24.1 | 0 | 0 | 0 | ||
| 3476 | DLBCL, immunoblastic | − | + | + | + | 4-04 | 8.62 | 0 | 0 | 0 | ||
| 3517 | DLBCL, immunoblastic | ND | ND | ND | − | 3-23 | 7.80 | 0 | 0 | 0 | ||
| 3525 | DLBCL, immunoblastic | − | + | − | − | 4-34 | 2.12 | 0 | 0 | 0 | ||
| 2890 | BL/BLL | ND | ND | ND | − | 4-61 | 12.0 | 12 | 3 | 20 | ||
P-PTLD indicates polymorphic PTLD; DLBCL, diffuse large B-cell lymphoma; ND, not determined; and BL/BLL, Burkitt lymphoma/Burkitt-like lymphoma.